IOL CHEMICALS & PHARM. | RAYMED LABS | IOL CHEMICALS & PHARM./ RAYMED LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 13.8 | -7.7 | - | View Chart |
P/BV | x | 1.6 | - | - | View Chart |
Dividend Yield | % | 1.0 | 0.0 | - |
IOL CHEMICALS & PHARM. RAYMED LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IOL CHEMICALS & PHARM. Mar-23 |
RAYMED LABS Mar-23 |
IOL CHEMICALS & PHARM./ RAYMED LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 537 | 2 | 26,308.8% | |
Low | Rs | 272 | 1 | 18,268.5% | |
Sales per share (Unadj.) | Rs | 377.6 | 0 | - | |
Earnings per share (Unadj.) | Rs | 23.7 | -0.4 | -5,918.0% | |
Cash flow per share (Unadj.) | Rs | 31.6 | -0.4 | -8,167.8% | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 256.8 | -5.4 | -4,755.3% | |
Shares outstanding (eoy) | m | 58.71 | 4.27 | 1,374.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.1 | 0 | - | |
Avg P/E ratio | x | 17.1 | -4.4 | -386.9% | |
P/CF ratio (eoy) | x | 12.8 | -4.6 | -281.2% | |
Price / Book Value ratio | x | 1.6 | -0.3 | -481.5% | |
Dividend payout | % | 16.9 | 0 | - | |
Avg Mkt Cap | Rs m | 23,743 | 8 | 314,795.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1,682 | 0 | 442,657.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 22,171 | 0 | - | |
Other income | Rs m | 256 | 0 | 121,952.4% | |
Total revenues | Rs m | 22,427 | 0 | 10,679,619.0% | |
Gross profit | Rs m | 2,257 | -2 | -121,328.0% | |
Depreciation | Rs m | 462 | 0 | 923,200.0% | |
Interest | Rs m | 165 | 0 | - | |
Profit before tax | Rs m | 1,887 | -2 | -110,321.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 495 | 0 | - | |
Profit after tax | Rs m | 1,391 | -2 | -81,368.4% | |
Gross profit margin | % | 10.2 | 0 | - | |
Effective tax rate | % | 26.2 | 0 | - | |
Net profit margin | % | 6.3 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,667 | 0 | 19,333,000.0% | |
Current liabilities | Rs m | 5,025 | 1 | 558,355.6% | |
Net working cap to sales | % | 20.9 | 0 | - | |
Current ratio | x | 1.9 | 0.1 | 3,462.5% | |
Inventory Days | Days | 43 | 0 | - | |
Debtors Days | Days | 8 | 0 | - | |
Net fixed assets | Rs m | 11,017 | 2 | 729,629.1% | |
Share capital | Rs m | 587 | 43 | 1,373.7% | |
"Free" reserves | Rs m | 14,490 | -66 | -22,024.8% | |
Net worth | Rs m | 15,077 | -23 | -65,382.5% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 20,684 | 2 | 1,325,891.0% | |
Interest coverage | x | 12.5 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.1 | 0 | - | |
Return on assets | % | 7.5 | -109.5 | -6.9% | |
Return on equity | % | 9.2 | 7.4 | 124.5% | |
Return on capital | % | 13.6 | 7.4 | 183.7% | |
Exports to sales | % | 26.7 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 5,930 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 5,930 | 0 | - | |
Fx outflow | Rs m | 6,052 | 0 | - | |
Net fx | Rs m | -122 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,223 | -2 | -74,554.9% | |
From Investments | Rs m | -1,200 | 2 | -73,170.7% | |
From Financial Activity | Rs m | -41 | NA | - | |
Net Cashflow | Rs m | -18 | 0 | - |
Indian Promoters | % | 48.2 | 28.4 | 169.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 1.7 | 1.0 | 177.1% | |
FIIs | % | 1.4 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 51.8 | 71.6 | 72.3% | |
Shareholders | 130,003 | 1,504 | 8,643.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare IOL CHEMICALS & PHARM. With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | IOL CHEMICALS & PHARM. | RAYMED LABS. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.95% | 0.00% | 1.00% |
1-Month | 6.80% | 9.63% | 1.07% |
1-Year | 1.69% | 17.16% | 53.70% |
3-Year CAGR | -12.59% | 36.97% | 14.66% |
5-Year CAGR | 16.44% | -0.08% | 19.26% |
* Compound Annual Growth Rate
Here are more details on the IOL CHEMICALS & PHARM. share price and the RAYMED LABS. share price.
Moving on to shareholding structures...
The promoters of IOL CHEMICALS & PHARM. hold a 48.2% stake in the company. In case of RAYMED LABS. the stake stands at 28.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of IOL CHEMICALS & PHARM. and the shareholding pattern of RAYMED LABS..
Finally, a word on dividends...
In the most recent financial year, IOL CHEMICALS & PHARM. paid a dividend of Rs 4.0 per share. This amounted to a Dividend Payout ratio of 16.9%.
RAYMED LABS. paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of IOL CHEMICALS & PHARM., and the dividend history of RAYMED LABS..
For a sector overview, read our pharmaceuticals sector report.
Japan's Nikkei 225 led gains in Asia as markets in the region rose across the board, following Wall Street's continued rally for a second straight day.